Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Troglitazone
Cat. No.:
OB0225LY-0324
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Troglitazone is a thiazolidinediones drug that is mainly used to improve insulin sensitivity and regulate lipid metabolism.
Synonym:
CS-045; Romozin; Rezulin; Romglizone; Noscal; Prelay; 97322-87-7
CAS No.:
97322-87-7
Formula:
C24H27NO5S
Formula Weight:
441.54
Specification
Relative Density:
1.266 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Troglitazone can be used in metabolic disease research or play an important role in diabetes modeling.
Library Information
Targets:
PPAR family
Receptors:
PPAR; PPARγ
Pathways:
Metabolism; Apoptosis; DNA damage/DNA repair; Autophagy
Plate Number:
AOCL-5
Plate Location:
b8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
18.33 mg/mL; 41.52 mM
Ethanol Max Solubility:
4.4 mg/mL; 10 mM
ALogP:
5.682
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
5
